Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TF2D-5a
- Development stage
- Preclinical
- Lead developer
- Priavoid
- Modality
- Peptides
- Administration
- Oral
01
Overview
TF2D-5a is an all-D-enantiomeric peptide ligand (21-mer) developed by Priavoid GmbH in collaboration with Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. It is designed to target and disassemble toxic tau protein aggregates into harmless physiological tau monomers, acting via a thermodynamic mode of action. TF2D-5a is a derivative of TF2D-5, featuring five additional D-arginine residues at the C-terminus to enhance cell penetration. It has demonstrated nanomolar binding affinity to tau, inhibition of tau aggregation in vitro and in cell-based assays, and blood-brain barrier penetration. The compound is being developed as a potential disease-modifying treatment for Alzheimer's disease and other tauopathies.
- Other names
- dGGyqilfkipGGhihrrrrr
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on TF2D-5a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TF2D-5a.